What does DSIP (Intranasal) stack well with?

For sourcing / quality / procurement protocols, DSIP (Intranasal) pairs with compounds on complementary pathways: BPC-157, TB-500, GHK-Cu. These pairings are selected because they engage independent receptor systems from DSIP (Intranasal)'s primary mechanism (Same DSIP molecule delivered intranasally), producing additive or synergistic effects rather than receptor competition.

What is the regulatory status of DSIP (Intranasal)?

DSIP (Intranasal) regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level preclinical. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For sourcing and quality-control use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does DSIP (Intranasal)'s half-life affect dosing?

DSIP (Intranasal) has a plasma half-life of Rapid CNS uptake via olfactory route, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1 spray before sleep dosing at 100-300 mcg per dose explains the typical onset timeline for sourcing and quality-control endpoints.

What are the safety considerations for DSIP (Intranasal)?

Excellent tolerability. Mild nasal irritation possible. For sourcing and quality-control use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. DSIP (Intranasal)'s Rapid CNS uptake via olfactory route pharmacokinetic profile and intranasal administration route influence the side-effect profile in predictable ways.

Should I cycle DSIP (Intranasal)?

Standard cycle for DSIP (Intranasal) is 8–12 weeks of 1 spray before sleep 100-300 mcg dosing via intranasal, followed by a 4 week complete off-period. The off-period is calibrated to DSIP (Intranasal)'s Rapid CNS uptake via olfactory route half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Home/ Compounds/ DSIP (Intranasal)

DSIP (Intranasal)

Sourcing Guide

Procurement-quality evaluation of DSIP (Intranasal) centres on six markers: lot-specific COA availability, HPLC purity ≥98%, mass spec confirmation matching 848 Da, endotoxin testing for injectable routes, vendor regulatory disclosure, and cold-chain shipping options. Same DSIP molecule delivered intranasally The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions.. The QC discipline applies regardless of the application; sourcing standards do not relax for any particular use case.

Sourcing / Quality / Procurement Applications

Pricing AnalysisStorage ProtocolShelf LifeBAC Water SourcingVendor Comparison

Key Takeaways

Procurement lens: DSIP (Intranasal) sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching 848 Da.
Mechanism: Same DSIP molecule delivered intranasally.
Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days.
Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger).
Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.

Sourcing / Quality / Procurement Mechanism

Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. Quality control discipline for DSIP (Intranasal) starts with mechanism understanding: which assays detect counterfeits, which impurities matter for the intended use, and which storage conditions preserve activity. The subsections work through HPLC purity, COA evaluation, reconstitution protocol, and vendor selection.

COA evaluation and red flags

Acceptable DSIP (Intranasal) certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.

Reconstitution and storage protocols

DSIP (Intranasal) is typically supplied lyophilised in glass vials for reconstitution with bacteriostatic water. Standard reconstitution: dissolve at 1–2 mg/mL, store reconstituted material at 4°C, and use within 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Lyophilised storage at −20°C extends shelf life to 18–24 months for most peptides in this class.

Vendor tier comparison and price discipline

Three vendor tiers operate in the DSIP (Intranasal) market: pharmaceutical-grade compounded prescription (physician-supervised, full COA, ICP-MS where relevant, highest cost), reputable research-chemical vendors (full COA, lot-specific, mid-tier cost), and grey-market unverified sources (template or absent COA, unverifiable supply chain, lowest cost). The price differential between tiers is roughly 3–5x; the quality differential is substantially larger and concentrated in the bottom tier.

Sourcing / Quality / Procurement Applications

Lyophilisation Quality

Sourcing DSIP (Intranasal) for lyophilisation quality use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Shelf Life

Pharmaceutical-grade compounded DSIP (Intranasal) is the lowest-risk sourcing path for shelf life use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.

Vendor Comparison

For users targeting vendor comparison, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

Storage Protocol

Sourcing DSIP (Intranasal) for storage protocol use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	100-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	60-300 mcg	4–6 weeks initial cycle
Sourcing Guide focus	Intranasal	100-300 mcg	1 spray before sleep
Maintenance phase	Intranasal	70-300 mcg	Ongoing with periodic pauses

Dose timing for DSIP (Intranasal) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

DSIP (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.

DSIP (Intranasal) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with DSIP (Intranasal)'s mechanism in sourcing / quality / procurement protocols.
DSIP (Intranasal) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with DSIP (Intranasal)'s mechanism in sourcing / quality / procurement protocols.
DSIP (Intranasal) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with DSIP (Intranasal)'s mechanism in sourcing / quality / procurement protocols.
DSIP (Intranasal) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with DSIP (Intranasal)'s mechanism in sourcing / quality / procurement protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical

Excellent tolerability. Mild nasal irritation possible.

Lens-specific safety considerations for sourcing / quality / procurement use of DSIP (Intranasal): Excellent tolerability. Mild nasal irritation possible. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

DSIP — characterisation and effects on sleep

PMID 6324019

DSIP (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
DSIP (Intranasal)	Neuropeptide (sleep, intranasal)	Rapid CNS uptake via olfactory route	Sourcing Guide
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Reconstitution best practices?

Use sterile bacteriostatic water (0.9% benzyl alcohol). Inject the BAC water down the side of the vial, not directly onto the lyophilised powder. Allow gentle dissolution; do not shake vigorously — swirl the vial. Label the reconstituted vial with concentration and date.

Lot variability across orders?

Even reputable vendors show some lot-to-lot variability. The QC-disciplined practice is to spot-check a fresh COA against the prior lot when re-ordering, and to track perceived response across lots. Substantial drift in subjective effects on a stable dose with a stable protocol often traces back to material quality rather than physiology.

What should I check on a DSIP (Intranasal) COA?

Acceptable certificates: lot-specific (not template), HPLC purity ≥98%, mass spec confirmation matching 848 Da, endotoxin testing for injectable routes, accredited third-party lab issuance. Template COAs and missing endotoxin data are red flags.

Pharmaceutical-grade versus research-grade?

Pharmaceutical-grade is GMP-manufactured, COA-backed, prescription-dispensed material with comprehensive quality assurance. Research-grade is laboratory-purpose, COA-backed, not dispensed under prescription. Quality varies substantially between research-grade vendors; pharmaceutical-grade has a tighter quality distribution and a higher price.

What is DSIP (Intranasal)?

DSIP (Intranasal) (also known as Delta Sleep-Inducing Peptide — Nasal) is a 9-residue neuropeptide (sleep, intranasal) with a molecular weight of 848 Da and a plasma half-life of Rapid CNS uptake via olfactory route. Same DSIP molecule delivered intranasally. The olfactory and trigeminal nerve pathways allow direct CNS access, sidestepping the BBB and producing faster onset on sleep-relevant brain regions. The compound is studied primarily in the sourcing / quality / procurement domain for the applications outlined above.

What is the evidence base for DSIP (Intranasal)?

DSIP (Intranasal)'s evidence base sits at preclinical. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The sourcing / quality / procurement interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Clinical Protocol

Start a DSIP (Intranasal) Protocol

Alukard provides GMP-certified physician-supervised sourcing with GMP-certified DSIP (Intranasal) and Pharmaceutical-grade compounds with full COA documentation.

Get Protocol

Quick Facts

Molecular weight: 848 Da
Sequence length: 9 aa
Half-life: Rapid CNS uptake via olfactory route
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical

Stack Partners

BPC-157

TB-500

GHK-Cu

Ipamorelin

Semax

Research Note

All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

GMP-certified physician-supervised sourcing

Start Your Sourcing / Quality / Procurement Protocol for DSIP (Intranasal)

Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised